よむ、つかう、まなぶ。
会議資料 (228 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00046.html |
| 出典情報 | 医療上の必要性の高い未承認薬・適応外薬検討会議（第68回 5／25）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
要望番号；IV-158
temozolomide and radiotherapy in an aggressive ACTH pituitary adenoma. Case Reports
Endocrinology. 2017.
１０）Lim S, et al. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol. 2006,
7, 518-520.
１１）Losa M, et al. Temozolomide therapy in patients with aggressive pituitary adenomas or
carcinomas. Journal of Neurooncology. 2016, 126, 519-525.
１２）Luo M, et al. Clinical efficacy of temozolomide and its predictors in aggressive pituitary
tumors and pituitary carcinomas: A systematic review and meta-analysis. Front Neurol. 2021,
12.
１３）Matsuoka CK, et al. Radiotherapy with concurrent temozolomide for the management of
extraneural metastases in pituitary carcinoma. Pituitary. 2016, 19(4), 415-421.
１４）McCormack A, et al. Treatment of aggressive pituitary tumours and carcinomas: results of a
European Society of Endocrinology (ESE) survey 2016. European Journal of Endocrinology.
2018, 178(3), 265-276.
１５）Murakami M, et al. A mechanism of acquiring temozolomide resistance during transformation
of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
Neurosurgery. 2011, 68(6), E1761-E1767.
１６）Raverot G, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary
carcinomas: a French multicenter experience. Journal of Clinical Endocrinology and
Metabolism. 2010, 95(10), 4592-4599.
１７）Raverot G, et al. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of
temozolomide treatment. Clinical Endocrinology. 2012, 76, 769-775.
１８）Raverot G, et al. European Society of Endocrinology Clinical Practice Guidelines for the
management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018, 178,
G1-G24.
１９）Raverot G, et al. Aggressive pituitary tumours and pituitary carcinomas. Nat Rev Endocrinol.
2021, 17(11), 671-684.
２０）Sansur CA, et al. Pituitary carcinoma. Semin Oncol. 2010, 37, 591-593.
２１）Zhong C, et al. Pituitary atypical adenoma or carcinoma sensitive to temozolomide combined
with radiation therapy: a case report of early identification and management. Turk Neurosurg.
2014, 24(6), 963-966.
２２）西岡宏, 他. 間脳・下垂体腫瘍の治療 薬物治療 下垂体癌. 日本臨牀. 2011, 69(増刊号
2), 212-216.
２３）日本内分泌学会. 内分泌代謝科専門医研修ガイドブック. 診断と治療社. 2018.（日本
内分泌学会, 2018a）
２４）日本内分泌学会. 間脳下垂体機能障害の診断と治療の手引き（平成 30 年度改訂）.
2018.（日本内分泌学会, 2018b）
19
228/370
temozolomide and radiotherapy in an aggressive ACTH pituitary adenoma. Case Reports
Endocrinology. 2017.
１０）Lim S, et al. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol. 2006,
7, 518-520.
１１）Losa M, et al. Temozolomide therapy in patients with aggressive pituitary adenomas or
carcinomas. Journal of Neurooncology. 2016, 126, 519-525.
１２）Luo M, et al. Clinical efficacy of temozolomide and its predictors in aggressive pituitary
tumors and pituitary carcinomas: A systematic review and meta-analysis. Front Neurol. 2021,
12.
１３）Matsuoka CK, et al. Radiotherapy with concurrent temozolomide for the management of
extraneural metastases in pituitary carcinoma. Pituitary. 2016, 19(4), 415-421.
１４）McCormack A, et al. Treatment of aggressive pituitary tumours and carcinomas: results of a
European Society of Endocrinology (ESE) survey 2016. European Journal of Endocrinology.
2018, 178(3), 265-276.
１５）Murakami M, et al. A mechanism of acquiring temozolomide resistance during transformation
of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
Neurosurgery. 2011, 68(6), E1761-E1767.
１６）Raverot G, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary
carcinomas: a French multicenter experience. Journal of Clinical Endocrinology and
Metabolism. 2010, 95(10), 4592-4599.
１７）Raverot G, et al. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of
temozolomide treatment. Clinical Endocrinology. 2012, 76, 769-775.
１８）Raverot G, et al. European Society of Endocrinology Clinical Practice Guidelines for the
management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018, 178,
G1-G24.
１９）Raverot G, et al. Aggressive pituitary tumours and pituitary carcinomas. Nat Rev Endocrinol.
2021, 17(11), 671-684.
２０）Sansur CA, et al. Pituitary carcinoma. Semin Oncol. 2010, 37, 591-593.
２１）Zhong C, et al. Pituitary atypical adenoma or carcinoma sensitive to temozolomide combined
with radiation therapy: a case report of early identification and management. Turk Neurosurg.
2014, 24(6), 963-966.
２２）西岡宏, 他. 間脳・下垂体腫瘍の治療 薬物治療 下垂体癌. 日本臨牀. 2011, 69(増刊号
2), 212-216.
２３）日本内分泌学会. 内分泌代謝科専門医研修ガイドブック. 診断と治療社. 2018.（日本
内分泌学会, 2018a）
２４）日本内分泌学会. 間脳下垂体機能障害の診断と治療の手引き（平成 30 年度改訂）.
2018.（日本内分泌学会, 2018b）
19
228/370